---
title: "Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | CRIS Stock News"
description: "Curis, Inc. (NASDAQ: CRIS) announced the approval of inducement stock options for its new Chief Medical Officer, Dr. Ahmed Hamdy, allowing him to purchase 200,000 shares at the closing price on May 1,"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/238994634.md"
published_at: "2025-05-06T22:16:00.000Z"
---

# Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | CRIS Stock News

> Curis, Inc. (NASDAQ: CRIS) announced the approval of inducement stock options for its new Chief Medical Officer, Dr. Ahmed Hamdy, allowing him to purchase 200,000 shares at the closing price on May 1, 2025. The options have a 10-year term and vest over four years. This grant is part of Dr. Hamdy's employment agreement and is outside the company's existing stock incentive plan. Curis focuses on developing emavusertib, an IRAK4 inhibitor, currently in clinical trials for various cancers.

, /PRNewswire/ --Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Board of Directors of Curis approved the grant of inducement stock options to its newly appointed Chief Medical Officer, Dr. Ahmed Hamdy to purchase 200,000 shares of Curis common stock, with a grant date of May 1, 2025 (the "Inducement Grant").

The Inducement Grant has an exercise price per share equal to the closing price of the Company's common stock on May 1, 2025. The Inducement Grant has a 10 year term and vests over four years, with 25% of the award vesting on the first anniversary of the grant date and an additional 6.25% of the award vesting on each successive three-month period thereafter, subject to Dr. Hamdy's continued service with the Company through the respective vesting dates. Dr.Hamdy's stock option was granted as an inducement equity award outside of the Company's Fifth Amended and Restated 2010 Stock Incentive Plan and was made as an inducement material to his acceptance of employment with the Company.

**About Curis, Inc.**

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the TakeAim Leukemia Phase 1/2 study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), and as a frontline combination therapy with venetoclax and azacitidine in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL.Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.

SOURCE Curis, Inc.

### Related Stocks

- [CRIS.US - Curis](https://longbridge.com/en/quote/CRIS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Curis 公司宣布即将召开的股东特别会议的日期 | 居里公司将于 2026 年 3 月 17 日以虚拟方式召开股东特别会议。股东将对多个提案进行投票，包括增加授权股份、优先股转换和认股权证行使、2026 年激励计划以及延期提案。此公告由公共技术公司生成，仅供参考 | [Link](https://longbridge.com/en/news/275367398.md) |
| 居里宣布完成总计高达 8080 万美元的私人配售，所得总收益 \| CRIS 股票新闻 | 居里公司成功完成了一项私募融资，筹集了高达 8080 万美元的总收益，由南塔哈拉资本和其他机构投资者主导。初始总收益约为 2020 万美元。这笔资金将支持 emavusertib 的开发，这是一种小分子 IRAK4 和 FLT3 抑制剂，目 | [Link](https://longbridge.com/en/news/272081640.md) |
| Curis Inc. 宣布特别股东大会的日期 | 居里公司将于 2026 年 3 月 17 日召开特别股东大会。议程包括投票增加授权股份数量、增加授权普通股、批准 2026 年激励计划，以及提议休会 | [Link](https://longbridge.com/en/news/275367391.md) |
| 居里公司宣布私人配售定价，总计高达 8080 万美元的总收益 \| CRIS 股票新闻 | 居里公司（NASDAQ: CRIS）宣布进行私募融资，计划筹集高达 8080 万美元的总收入，其中初始收入约为 2020 万美元。此次融资涉及向机构投资者和内部人士出售 B 系列可转换优先股和认股权证。该交易预计将在 2026 年 1 月  | [Link](https://longbridge.com/en/news/271799124.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
